Insilico Medicine to present Phase 1 ISM6331 data at ESMO
July 28, 2026 | 15:29
Insilico Medicine announced an oral presentation at ESMO 2026 featuring first-in-human results for ISM6331, an AI-designed pan-TEAD inhibitor targeting the Hippo pathway in mesothelioma and advanced solid tumours.
Mobile Version